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Abstract
Duchenne muscular dystrophy (DMD) is a lethal X-linked disorder caused by mutations in the dystrophin gene, which
encodes a cytoskeletal protein, dystrophin. Creatine kinase (CK) is generally used as a blood-based biomarker for muscular
disease including DMD, but it is not always reliable since it is easily affected by stress to the body, such as exercise.
Therefore, more reliable biomarkers of muscular dystrophy have long been desired. MicroRNAs (miRNAs) are small, ,22
nucleotide, noncoding RNAs which play important roles in the regulation of gene expression at the post-transcriptional
level. Recently, it has been reported that miRNAs exist in blood. In this study, we hypothesized that the expression levels of
specific serum circulating miRNAs may be useful to monitor the pathological progression of muscular diseases, and
therefore explored the possibility of these miRNAs as new biomarkers for muscular diseases. To confirm this hypothesis, we
quantified the expression levels of miRNAs in serum of the dystrophin-deficient muscular dystrophy mouse model, mdx, and
the canine X-linked muscular dystrophy in Japan dog model (CXMDJ), by real-time PCR. We found that the serum levels of
several muscle-specific miRNAs (miR-1, miR-133a and miR-206) are increased in both mdx and CXMDJ. Interestingly, unlike
CK levels, expression levels of these miRNAs in mdx serum are little influenced by exercise using treadmill. These results
suggest that serum miRNAs are useful and reliable biomarkers for muscular dystrophy.
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Introduction
Duchenne muscular dystrophy (DMD) is a lethal X-linked
disorder caused by mutations in the dystrophin gene, which encodes
a cytoskeletal protein, dystrophin[1]. The absence of dystrophin
results in progressive degeneration of skeletal and cardiac muscle
with fibrotic tissue replacement, fatty infiltration, and subsequent
early death by respiratory or heart failure[2,3]. Creatine kinase
(CK) is an enzyme related to energy metabolism present in various
types of cells[4]. CK is commonly used as a blood-based
biomarker for muscular dystrophy to evaluate the level of muscle
damage and necrosis, and the efficacy of potential therapies, but it
is not always reliable since it is easily affected by stress to the body,
such as exercise[5,6,7]. Other markers for muscular dystrophy,
such as myoglobin, aldolase or lactate dehydrogenase, also have
the same problem. Therefore, more reliable biomarkers of
muscular dystrophy have long been desired.
MicroRNAs (miRNAs) are small, ,22 nucleotide, noncoding
RNAs which play important roles in the regulation of gene
expression at the post-transcriptional level[8]. Recently, it has been
reported that specific miRNAs in blood are promising biomarkers
for cancer, liver injury and heart failure [9,10,11]. These studies
showed that the levels of specific circulating miRNAs are associated
with the development of these pathological processes. It has also
been reported that miRNAs are released from cells through an
exosomal-mediated pathway[12], suggesting that circulating miR-
NAs are packaged in exosomes, which protects them from RNases.
We hypothesized that the expression levels of specific serum
circulating miRNAs may be useful to monitor the pathological
progression of muscular diseases, and therefore explored the
possibility of these miRNAs as new biomarkers for muscular
diseases. Here, we demonstrate that the serum levels of several
muscle-specific miRNAs are increased in the dystrophin-deficient
muscular dystrophy mouse model, mdx, as well as the canine
X-linked muscular dystrophy in Japan dog model (CXMDJ)
[13,14,15]. These results suggest that serum miRNAs are useful as
markers for muscular dystrophy.
Results
To explore the possibility of miRNA as a biomarker for DMD,
we quantified the expression levels of several miRNAs in the serum
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indicated as either cycle threshold (Ct) (Figure 1a) or fold
expression compared to wild-type (Figure S1). The Ct values of
the ubiquitously expressed miR-16, brain-rich miR-132 [16] and
small nucleolar RNA 202 (sno202) did not show any significant
differences between wild-type and mdx serum (Figure 1a). In
contrast, muscle-specific miR-1, -133a and -206 [17,18,19] were
significantly increased in mdx (Figure 1a). The expression levels of
these miRNAs in mdx were 10- to 100-fold higher than in wild-type
controls (Figure S1). In Figure 1, the data are shown without
normalization by an internal control RNA. Although small
nuclear RNA U6, sno202 and ubiquitously expressed miRNA,
such as miR-16, are often used as an internal control for miRNA
analysis, there is currently no consensus for a serum internal
control miRNA for real-time PCR analysis. Indeed, we examined
the expression of U6 but found it was undetectable in serum (data
not shown), and sno202 and miR-16 revealed no significant
difference between wild-type and mdx (Figure 1a and Figure S1).
In addition, miR-16 was more abundant than sno202 in serum
(Figure 1a). Therefore, we employed miR-16 as the internal
control for normalization of muscle-specific miRNAs in serum in
the subsequent studies.
We also confirmed the accuracy of miR-16 as an internal
control by using exogeneous miRNA (spiked-in miRNA). C. elegans
miRNA-39 (cel-miR-39) was used as a spiked-in miRNA because
of the lack of sequence homology to mouse miRNAs. Synthetic
cel-miR-39 was spiked into serum after the addition of denaturing
solution including RNase inhibitors. Then, miRNAs were isolated
and the levels of cel-miR-39, miR-16, -1, -133a and -206 were
determined by real-time PCR (Figure S2). In three-repeated
experiments, the quantities of cel-miR-39 and miR-16 showed
similar levels each time (Figure S2a). Furthermore, the
expression levels of miR-1, -133a and -206 were calculated by
normalization with cel-miR-39 or miR-16, individually (Figure
S2b). The expression levels of miR-1, -133a and -206 were highly
elevated in mdx, and the results were consistent between
normalization with cel-miR-39 and miR-16.
It is conceivable that leakage or secretion from skeletal muscle
fibers is the major cause of the increase in muscle-specific miRNAs
in serum, but there remains the possibility that these miRNAs are
excessively expressed in dystrophic skeletal muscle, which then
influences serum expression levels. To investigate this possibility,
we examined the expression level of these miRNAs in the skeletal
muscle (soleus: Sol, tibialis anterior: TA and diaphragm: DIA) of
mdx (Figure S3). Levels of ubiquitously expressed miR-16 were
not different among the muscles examined, but miR-1 and miR-
133a were significantly decreased in Sol and TA of mdx, although
the differences are less than 2-fold. On the other hand, miR-206
was significantly increased in mdx TA and DIA, but not in Sol, and
this increase of miR-206 in some mdx muscles could be related to a
previously reported role for miR-206 in muscle regeneration[20].
Since miR-1 and -133a levels were highly elevated in mdx serum,
although they were not increased in mdx skeletal muscle, suggests
that the increase of muscle-specific miRNAs in mdx serum is
caused by an increase in leakage or secretion of miRNAs from
muscle.
Since it is very important to investigate whether muscle-specific
miRNA levels are affected by exercise like as CK, we compared
CK and miRNA levels in mice serum after exercise using a
treadmill. Both CK and miRNA were increased after the treadmill
exercise (Figure 1b, left, normalized to wild-type control),
however miRNAs appeared to be less affected. When the increase
in miRNAs were corrected by the data before exercise in each
group (Figure 1b, right, normalized by each control), CK showed
almost a 60-fold increase after exercise, whereas the change of
muscle-specific miRNA levels was less than 10-fold.
CXMDJ is a well characterized dog model of DMD, which
shows severe and progressive symptoms[13,14,15]. We therefore
analyzed the expression levels of miRNAs in normal, carrier
(females possessing a mutant dystrophin gene on one of two X-
chromosomes) and CXMDJ dog serum at various ages. The Ct
value of these miRNAs in CXMDJ was significantly smaller than
age-matched controls (Figure S4). Relative expression levels
corrected by miR-16 are shown in Figure 2. These miRNAs are
apparently able to distinguish CXMDJ from age-matched normal
dogs. Shimatsu et al. previously reported that the CK concentra-
tion of CXMDJ dogs do not increase with age [21]. Thus, our
results of these miRNA levels are consistent with the CK levels in
this model.
Our data indicate that the levels of miR-1, -133a and -206
relative to miR-16 are increased in the serum of two animal
models of muscular dystrophy, mdx and CXMDJ. It is very
intriguing that serum miRNA were less affected by stress, such as
exercise, compared with CK. In conclusion, muscle-specific
miRNAs in serum may be useful biological markers for muscular
dystrophy which are more reliable than CK, and further
investigations are required to clarify the molecular mechanisms
by which miRNAs are released from the inside of cells into serum.
Discussion
Recently, several studies have reported that miRNAs in serum
are promising biomarkers for diseases, such as cancers, liver injury
or heart failure [9,10,11]. CK is commonly used as a biomarker of
muscular diseases to evaluate the level of muscle damage and
necrosis, and the efficacy of potential therapies, but it is not always
reliable since it is easily affected by stress to the body, such as
exercise [5,6,7]. Therefore, more reliable biomarkers of muscular
dystrophy have long been desired. We hence investgigated
whether serum miRNAs are useful for monitoring the pathological
condition of muscular diseases. In this report, we demonstrate that
the serum levels of several muscle-specific miRNAs are increased
in two dystrophin-deficient muscular dystrophy animal models.
Importantly, we show that the levels of these miRNAs are much
less affected by stress to the body compared with CK levels.
To investigate the mechanism of the increase of miRNA
expression, we also examined the expression level of miR-1, miR-
133a and miR-206 in the skeletal muscle of mdx (Figure S3). miR-1
and-133aweresignificantlydecreasedinSoland TAofmdx.Onthe
other hand, miR-206 was significantly increased in TA and DIA of
mdx. Our results suggest that the increase of muscle-specific
miRNAs in the serum of these DMD models is caused by an
increase in leakage or secretion of miRNAs from muscle, and not by
the change of expression in skeletal muscle. However, it is not yet
clear whether the increase of these miRNAs is caused by leakage or
secretion from muscle. It is conceivable that leakage from skeletal
muscle fibers is the major cause of the increase in muscle-specific
miRNAs in mdx serum, but it is hard to explain why these miRNAs
were not degraded by RNase. Mitchell et al. [10] showed that
synthetic miRNAs are immediately degraded in serum even though
endogenous circulating miRNAs are stably expressed in serum. To
explain these results, they suggested that miRNAs are released from
cells through an exosomal-mediated pathway. If circulating
miRNAs are secreted by an exosomal-mediated pathway, it is
possible that dystrophin is involved in the regulation of exosome
secretion and a lack of dystrophin results in increased miRNA
release. However, further investigation is required to clarify the
contribution of dystrophin in exosome secretion.
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mdx in this report is consistent with previous reports [20,22]. It is
intriguing that TA muscle of denervated mice also showed an
increase in miR-206 and a decrease in miR-1 and -133a [23].
Yuasa et al. [20] also showed that miR-206 expression was
increased after cardiotoxin-induced muscle regeneration and that
miR-206 contributes to muscle regeneration. Interestingly, it has
been showed that the expression levels of miR-206 in DMD
patients are not increased [24] or that the increase is not as large as
in mdx [22]. Although mdx mice are deficient in dystrophin, they do
not show lethality unlike in humans. Increased miR-206
expression levels in mdx therefore contribute to the different
phenotype between humans and mice. In addition, Williams et al.
[23] showed that expression of miR-206 delayes disease progres-
sion and promotes regeneration of neuromuscular synapses in
amyotrophic lateral sclerosis (ALS) model mice. Taken together,
these results indicate that gene therapy using miR-206 may be a
useful treatment for muscular diseases.
In this report, we focused on muscle-specific miRNAs and
found that they are significantly increased in serum of DMD
models. To investigate whether such an increase can be observed
in some myopathy models which do not have any effective
diagnosis markers, we also measured these muscle-specific
miRNAs in serum of steroid treated dogs. We found that serum
level of miR-1, -133a and -206 were not increased in steroid
treated dog did not show increase compared with non-treatment
controls (data not shown). Intriguingly, Lodes et al. [25] performed
microarray analysis with circulating miRNAs and found an
increase in specific miRNAs in serum of cancer patients.
Furthermore the miRNA expression patterns were able to
discriminate between healthy controls and cancer patients. Such
a microarray analysis may be useful for identifying diagnosis
markers for muscular diseases for which effective diagnosis
markers currently do not exist.
Materials and Methods
Ethics Statement
The dog study was approved by the Ethics Committee for the
Treatment of Middle-sized Laboratory Animals of the National
Institute of Neuroscience, National Center of Neurology and
Psychiatry, approval ID: 21-02 and 22-02. The mice study was
Figure 1. Elevation of muscle-specific miRNA levels in mdx mouse serum. (a) Expression levels of miRNAs in 8-week old male wild-type and
mdx serum. Ct was determined by real-time PCR. In these graphs, the longer bars on each plot indicate the mean, and the shorter bars indicate 6
SEM, n=5. Asterisk (*) indicates a significant difference (*, P,0.05; **, P,0.01, two-tailed Student’s t-test.). The actual P value for each test was
P=0.797 (miR-16), 0.222 (miR-132), 0.344 (sno202), 0.011 (miR-1), 0.007 (miR-133a) and 0.001 (miR-206). (b) CK and miRNA expression levels in wild-
type and mdx serum after treadmill exercise. Running on the treadmill was continued for 20 min. About 100 ml of blood was collected from the tail
vein at 0.5, 6 and 48 h after the exercise. Six days before the test, blood was collected as a control. Expression levels were normalized to the wild-type
control (left) or each individual control (right). Data are presented as mean 6 SEM, n=3. #: wild-type;N: mdx.
doi:10.1371/journal.pone.0018388.g001
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Laboratory Animals of the National Institute of Neuroscience,
National Center of Neurology and Psychiatry, approval ID:
2008011.
Animals and serum samples
All animals in this study were cared for and treated in
accordance with the guidelines provided by the Ethics Committee
for the Treatment Laboratory Animals of National Institute of
Neuroscience, or the Ethics Committee for the Treatment
Laboratory Middle-sized Animals of National Institute of
Neuroscience. Skilled experimental animal technicians, who have
special knowledge of methods to prevent unnecessary excessive
pain, handled the animals and assisted in the experiments.
As Duchenne muscular dystrophy (DMD) models, the X-
chromosome-linked muscular dystrophy (mdx) mouse and canine
X-linked muscular dystrophy in Japan (CXMDJ), Beagle-based
medium-sized dystrophic dogs, were used in this study. In
Figure 1a, whole body blood of male mdx mice (n=5) or age-
matched controls (strain C57BL/10; B10) (n=5) at 8 weeks were
collected from the abdominal vena cava under anesthesia. Blood
collection after the treadmill test (Figure 1b), was performed from
the tail vein of mdx (n=3) or age-matched control (n=3) under
anesthesia. The phenotype of CXMDJ has been reported
previously[13,14,15]. For analysis of the serum of CXMDJ dogs,
mutation carrier female dogs and wild-type control dogs (n=3, at
each age indicated in Figure 2), blood was collected from the
subcutaneous vein of the hindlimb, and whole blood was allowed
to stand for about 1 h at room temperature before centrifugation
at 1,800 g for 10 min at room temperature. The resultant serum
was dispensed into a 1.5 ml cryotube and stored at 280uC until
use.
RNA isolation and quantification of miRNA
Total RNA, including miRNA, was extracted from 50 mlo f
serum using the mirVana miRNA isolation kit (Ambion, Austin,
TX, USA) according to the manufacturer’s instructions, and
finally eluted with 50 ml of elution buffer provided by the
manufacturer. Five ml of total RNA was reverse transcribed using
the TaqMan miRNA Reverse Transcription kit (Applied Biosys-
tems, Foster City, CA, USA) and miRNA-specific stem-loop
primers (part of TaqMan miRNA assay kit; Applied Biosystems).
The expression levels of miRNA were quantified by real-time PCR
using individual miRNA-specific primers (part of TaqMan
miRNA assay kit; Applied Biosystems) with 7900HT Fast Real-
Time PCR System (Applied Biosystems) according to the
manufacturer’s instructions. There is no current consensus on
the use of an internal control for real-time PCR analysis of serum
miRNA. Therefore, we used fixed volumes of starting serum
(50 ml), buffer for the elution of RNA (50 ml) from starting serum,
and input into the RT reaction (5 ml) in each assay for technical
consistency. Data analysis was performed by SDS 2.1 real-time
PCR data analysis software (Applied Biosystems). Threshold was
fixed at 0.2 in each analysis for data consistency. The similarities of
linearity of primers for each target miRNA were confirmed by
using a dilution series of synthetic miRNAs.
Figure 2. Elevation of muscle-specific miRNAs in CXMDJ dog serum. CK activity and miRNA expression in the serum of normal, carrier and
dystrophy dogs (CXMDJ) at the indicated ages were determined. Expression levels of miR-1, miR-133a, miR-206 and miR-16 were determined by real-
time PCR, and levels of each muscle-specific miRNA (miR-1, miR-133a and miR-206) was corrected by miR-16 levels. Results are indicated as relative
expression to normal dogs at each age, and are presented as mean 6 SEM, n=3. w: weeks; m: months.
doi:10.1371/journal.pone.0018388.g002
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We followed the protocol previously reported by Mitchell et al.
[10] to determine endogenous miRNA levels with spiked-in
miRNA. Spiked-in miRNA was designed against C. elegans
microRNA-39 (cel-miR-39)(59-UCACCGGGUGUAAAUCAG-
CUU-39), and was synthesized by Sigma Aldrich Japan. Synthetic
cel-miR-39 was spiked into serum after the addition of denaturing
solution including RNase inhibitors. Isolation of total RNA,
including miRNA, and quantification of the expression levels of
miRNAs by real-time PCR were performed as described above.
Creatine kinase determination
Serum creatine kinase (CK) levels were assayed with the Fuji
Drychem system (Fuji Film Medical Co. Ltd, Tokyo, Japan)
according to the manufacturer’s instructions. Data was expressed
as units per liter (U/l).
Treadmill test
Mice were forced to run on a treadmill (MK-680S treadmill:
Muromachi Kikai, Tokyo, Japan) with an inclination of 0u at 5 m/
min for 5 min. Then, the speed was increased by 1 m/min every
minute for a further 15 min. After the running, blood was
immediately collected from the tail vein, as well as subsequently
collected at the indicated times.
Statistics
Statistical significances between groups were determined by the
two-tailed t-test, or one-way ANOVA with Bonferroni post hoc
test. Each analysis was performed by Prism 5 (Graphpad Software
Inc., San Diego, CA, USA).
Supporting Information
Figure S1 miRNA expression in 8-week old male wild-
type control and mdx serum. Expression levels of miRNAs
were determined by real-time PCR. Results are shown as relative
expression, and data are presented as mean 6 SEM, n=5.
(TIFF)
Figure S2 (a) Confirmation of the consistency of miRNA
isolation from serum. C. elegans miR-39 (cel-miR-39) was
chemically synthesized and added to the denatured mouse serum
samples. Total RNA was isolated from the mouse serum samples,
and the quantity of exogenous cel-miR-39 and endogenous miR-
16 were determined by real-time PCR. (b) Expression levels of
miR-1, -133a and -206 in wild-type control and mdx serum, which
were individually normalized by the cel-miR-39 spiked-in control
or the endogenous control, miR-16. Results are shown as relative
expression. The longer bars on each plot indicate the mean, and
the shorter bars indicate 6 SEM, n=3.
(TIFF)
Figure S3 miRNA expression in wild-type control and
mdx muscles. Expression levels of miR-1, -16, -133a and -206
in Soleus (Sol), tibialis anterior (TA) and diaphragm (DIA) were
determined by real-time PCR. Results are shown as relative
expression. sno202 was used as an internal control. Data are
presented as mean 6 SEM, n=4. Asterisk (*) indicates a
significant difference (*, P,0.05; P,0.01, two-tailed Student’s t-
test.). The actual P value for each test was P=0.024 (miR-1) and
0.010 (miR-206) in Sol; P=0.002 (miR-1), 0.008 (miR-133a) and
,0.001 (miR-206) in TA; P=0.006 (miR-206) in DIA.
(TIFF)
Figure S4 Expression levels of muscle-specific miRNAs
in the serum of normal, carrier and dystrophy dogs
(CXMDJ) at the indicated ages. Each Ct was determined by
real-time PCR. In these graphs, the longer bars on each plot
indicate the mean, and the shorter bars indicate 6 SEM, n=3.
Asterisk (*) and pound (#) indicate a significant difference
(*, P,0.05; **, P,0.01; ***, P,0.001 from normal: #,P ,0.05;
##,P ,0.01; ###,P ,0.001 from carrier, one-way ANOVA
with Bonferroni post hoc test). w: weeks; m: months.
(TIFF)
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